Publications by authors named "Chan Wung Kim"
Thyroid cancer is the most well-known type of endocrine cancer that is easily treatable and can be completely cured in most cases. Nonetheless, anti-cancer drug-resistant metastasis or recurrence may occur and lead to the failure of cancer therapy, which eventually leads to the death of a patient with cancer. This study aimed to detect novel thyroid cancer target candidates based on validating and identifying one of many anti-cancer drug-resistant targets in patient-derived sorafenib-resistant papillary thyroid cancer (PTC).
View Article and Find Full Text PDFArticle Synopsis
- Thyroid carcinoma is the most common type of endocrine cancer, with papillary thyroid carcinoma (PTC) making up about 80% of cases, yet treating advanced or recurring PTC is complex and challenging.
- This study identifies a critical factor, sarco/endoplasmic reticulum calcium ATPase (SERCA), necessary for the survival of therapy-resistant PTC cells, suggesting it as a new target for drug development.
- Researchers discovered new SERCA inhibitors that significantly reduced tumors in models of resistant PTC, indicating that combining these inhibitors with existing treatments like sorafenib or paclitaxel could enhance the effectiveness against aggressive cancer cells.
Drug resistance causes therapeutic failure in refractory cancer. Cancer drug resistance stems from various factors, such as patient heterogeneity and genetic alterations in somatic cancer cells, including those from identical tissues. Generally, resistance is intrinsic for cancers; however, cancer resistance becomes common owing to an increased drug treatment.
View Article and Find Full Text PDF